Overview

Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

Status:
Active, not recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Academic Thoracic Oncology Medical Investigators Consortium
University of Colorado, Denver
Collaborator:
University of Colorado, Denver